Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC81567 ST1072 Featured
ST1072 is a dual inhibitor of CerS4 and CerS6. ST1072 significantly reduces the ability of murine T cells to proliferate and produce IFN-γ. ST1072 can be used for hematologic malignancies research.
More description
DC68233 ATX-95 Featured
ATX-95 is an unsaturated ionizable lipid utilized in the formulation of lipid nanoparticles for drug delivery.
More description
DC67653 Imidazole cholesteryl ester (ICE) Featured
Imidazole cholesterol ester (ICE) is a sterol‑based ionizable cationic lipid invented by Translate‑Bio (WO2018/089790 A1) for mRNA‑loaded lipid‑nanoparticle (LNP) pulmonary delivery. It fuses an imidazole pH‑responsive headgroup with cholesterol via ester linkage. Typically formulated as a three‑component LNP (ICE : DOPE : DMG‑PEG2K = 60 : 35 : 5 mol ratio), ICE‑LNPs achieve high mRNA encapsulation (>80‑90 %), good nebulization stability and low toxicity. Upon cellular uptake, imidazole mediates endosomal escape; the ester bond degrades to yield cholesterol, conferring favorable biocompatibility. Animal studies demonstrate robust CFTR protein expression in bronchial and alveolar lung tissue after inhalation, making ICE promising for cystic‑fibrosis mRNA therapy.
More description
DC9575 IPA-3 Featured
IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).
More description
DC79352 Jun6504 Featured
Jun6504 is an enterovirus 2C inhibitor. Jun6504 shows potent and broad-spectrum antiviral activity against multiple strains of EV-D68 (EC50 = 250 nM), EV-A71 (EC50 = 502.4 nM), and CVB3 (EC50 = 1049 nM). Jun6504 improves paralysis score and weight gain in a neonatal mouse model of EV-D68 infection. Jun6504 reduces viral titers in the spinal cord and the infected quadriceps muscle. Jun6504 can be used for EV-D68 antiviral research.
More description
DC7266 Rilpivirine(R 278474, TMC 278) Featured
Rilpivirine(R 278474, TMC 278) is a type of anti-HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI).
More description
DC74253 MSG011 Featured
MSG011 is a potent, pan AMPK isoform activator with EC50 of 140.4 nM, 248.9 nM, 553.4 nM, and 472.9 nM for α1β1γ1, α1β2γ1, α2β1γ1, and α2β2γ1, respectively.
More description
DCL0002 HI-62 Featured
HI-62 is a cyclic-thiourea ionizable lipid reported as a lead component of onion-like multilamellar mRNA-LNPs. In the cited preprint, its E21 formulation supported high mRNA encapsulation, sustained reporter expression, frozen-storage stability and antitumor activity in a preclinical mRNA-vaccine model.
More description
DCL0003 Lipid 43 Featured
Lipid 43 is an ionizable lipid disclosed as Compound 43 in WO 2024/109794. In the patent's TMF30 formulation, mRNA-LNPs showed predominantly splenic reporter expression after administration in mice. Its structure, molecular formula, molecular weight and SMILES were assigned from the compound-specific synthesis scheme and checked against the reported proton count.
More description
DCL0001 Antioxidant lipid AO16 Featured
AO16 is a literature-reported antioxidant ionizable lipid derived from the SM-102 scaffold.
More description
DC81570 STAT3-IN-53 Featured
STAT3-IN-53 (Compound L20) is a STAT3 inhibitor with a Kd value of 6.16 μM. STAT3-IN-53 binds directly to the SH2 domain of STAT3, inhibits phosphorylation at the Y705 site without affecting the total STAT3 protein level, and suppresses the IL-6/JAK/STAT3 pathway. STAT3-IN-53 downregulates the transcription and expression of cyclin-D1 and c-Myc. STAT3-IN-53 induces cell cycle arrest and promotes Apoptosis. STAT3-IN-53 exhibits anticancer activity against colorectal cancer.
More description
DC60981 Fmoc-asp(ompe)-oh Featured
DC77043 KB-208 Featured
KB-208 is a phagocytosis inhibitor that improves immune thrombocytopenia (ITP) in mouse models at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum toxicity biomarkers. KB-208 can be used in immunology research.
More description
DC65648 Retatrutide (LY3437943) Featured
LY3437943 is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). LY3437943 inhibits for human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. LY3437943 can be used for the research of obesity.
More description
DC45933 Bumadizone Featured
Bumadizone is a non-steroidal anti-inflammatory drug (NSAID) and can relieve pain.
More description
DC70432 GHP-88309 Featured
GHP-88309 (GHP88309) is a non-nucleoside, broad-spectrum allosteric inhibitor of paramyxovirus polymerase with EC50 of 0.9 uM against HPIV3-JS RdRP.Demonstrates highly potent antiviral potency against HPIV3-JS and clinical isolates HPIV3-9R4 and HPIV3-10L3 in the primary cell/virus isolate system (EC50=0.07-0.08 uM), without cytotoxicity.GHP-88309 targets a conserved microdomain in the L protein, inhibiting de novo RNA synthesis.GHP-88309 is efficacious in well-differentiated human airway epithelium cultures grown at air-liquid interface (3D-ALI-HBTEC).GHP-88309 (150 mg/kg b.i.d.) is orally efficacious in HPIV disease surrogate model.GHP-88309 possesses unusual broad-spectrum activity against diverse paramyxoviruses including respiroviruses (i.e. HPIV1 and HPIV3) and morbilliviruses (i.e. MeV).
More description
DC75987 H052 Featured
H052 is a selective Staphylococcus aureus α-hemolysin (Hla) inhibitor. H052 binds to Hla monomers, disrupts the interaction with host cell membranes to block pore formation, inhibiting calcium ion influx, cytotoxicity, and inflammatory responses. H052 exhibits potency (EC50=30 nM in U937 cells) against Hla-induced calcium influx. H052 is promising for research of lung infections caused by S. aureus.
More description
DC68232 IRBM-Z-1 Featured
IRBM-Z-1 is a non-competitive allosteric inhibitor of the Zika virus (ZIKV) NS2B-NS3 protease, identified through phenotypic screening for ZIKV replication inhibitors. In vitro, IRBM-Z-1 inhibits recombinant ZIKV NS2B-NS3 protease with an IC50 of 1.8 ± 0.8 μM and binds the protease with a KD of 1.52 ± 0.75 μM. In ZIKV replicon assays, IRBM-Z-1 suppresses viral RNA replication with an EC50 of 6.0 ± 1.9 μM and inhibits ZIKV-induced cytopathic effects in cell culture with an EC50 of approximately 6.25 μM, while showing no significant cytotoxicity at concentrations up to 32 μM. Activity is strongly dependent on NS3 residue I156, with the I156T mutation markedly reducing potency.
More description
DCC2044 F0045(s) Featured
Novel influenza A hemagglutinin (HA) fusion inhibitor (EC 50 = 1.9 ± 0.3 μM), preventing HA from transitioning to the postfusion state at pH 5.0
More description
DC74461 Rentosertib Featured
INS018_055 (INS018-055) a selective small-molecule TRAF2- and NCK-interacting kinase (TNIK) inhibitor with Kd value of 4.32 nM and IC50 of 31 nM, inhibits TGF-β-induced α-SMA protein expression in MRC-5 cells with IC50 of 27.14 nM.
More description
DC60840 Lipid F10T5 Featured
F10T5 is a furan-derived ionizable lipid developed for mRNA delivery to the central nervous system through the meningeal lymphatic pathway. Its architecture incorporates an ionizable polyamine region and four hydrophobic tails containing acid-sensitive acetal linkages. Following subcutaneous administration near the deep cervical lymph nodes, F10T5 LNPs enabled functional mRNA expression in neurons, microglia, and astrocytes while producing relatively low signals in peripheral organs. Cre mRNA delivery resulted in tdTomato expression in approximately 8.93% of neurons, 7.0% of microglia, and 9.9% of astrocytes in mice. Compared with the co-lead lipid F11T6, F10T5 showed comparable total brain luciferase expression, stronger astrocyte transfection, and lower peripheral-organ distribution. Its activity was associated primarily with improved endosomal escape rather than increased cellular uptake. F10T5 remains a preclinical research lipid, and its repeat-dose safety, pharmacokinetics, and performance in larger animals require further evaluation.
More description
DC66455 Stanolone Featured
DC80100 5-Diazomethane quinoxaline Featured
5-Diazomethane quinoxaline is a novel derivatization reagent. 5-Diazomethane quinoxaline is used for the detection of phosphorylated metabolites.
More description
DC49932 FTT5 Featured
FTT5 is a lipid-like compound for efficient delivery of long mRNAs in vivo.
More description
DC28558 BCL6-IN-3 Featured
BCL6-IN-3 (example 20a) is a B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity, extracted from patent WO2018215801A1. BCL6-IN-3 (example 20a) exhibits a GI50 of 70 nM in SU-DHL4 cells.
More description
DCC1608 Cx08005 Featured
CX08005 is a competitive PTP1B inhibitor. CX08005 can directly enhance the action of insulin in vivo and in vitro and improve insulin resistance.
More description
DC34504 Amthamine Dihydrobromide Featured
Amthamine is a histamine receptor (H1R-H4R) agonist. Amthamine can produce liver congestion and necrosis of liver cells. Amthamine can be used to study the induction effect of H1R-H4 agonist on hepatotoxicity.
More description
DCC4830 Sod1-derlin-1 Inhibitor 56-20 Featured
SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1G93A-Derlin-1 complex with an IC50 value of 7.11 μM.
More description
DC43652 Merck-22-6 Featured
Merck-22-6(compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells
More description
DC79780 (S)-SCH-23390 hydrochloride Featured
(S)-SCH-23390 (hydrochloride) is the S-enantiomer of SCH-23390. SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively).
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X